Cargando…

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’

Detalles Bibliográficos
Autores principales:	Dankner, Matthew, Rose, April A. N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943260/ https://www.ncbi.nlm.nih.gov/pubmed/29563631 http://dx.doi.org/10.1038/s41416-018-0012-2

Ejemplares similares

Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
por: Shinozaki, Eiji, et al.
Publicado: (2018)

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
por: Shinozaki, Eiji, et al.
Publicado: (2017)

The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
por: Yuan, Zi-Xu, et al.
Publicado: (2013)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
por: Kang, Sora, et al.
Publicado: (2023)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
por: Kaneko, Mika K., et al.
Publicado: (2018)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
por: Ohishi, Tomokazu, et al.
Publicado: (2020)

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
por: Yang, Zu-Yao, et al.
Publicado: (2012)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
por: Ying, Hou-Qun, et al.
Publicado: (2015)

KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
por: Morales-Estevez, Cristina, et al.
Publicado: (2016)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
por: van Helden, E. J., et al.
Publicado: (2017)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2022)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
por: Derer, Stefanie, et al.
Publicado: (2013)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line
por: Fiala, Ondrej, et al.
Publicado: (2018)

Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer
por: Deyati, Avisek, et al.
Publicado: (2015)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer
por: Mao, C, et al.
Publicado: (2010)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition
por: Ottaiano, Alessandro, et al.
Publicado: (2013)

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
por: Martin, V, et al.
Publicado: (2013)

Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
por: Hsieh, Meng-Chiao, et al.
Publicado: (2018)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
por: Altamura, Gennaro, et al.
Publicado: (2022)

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
por: Concha-Benavente, Fernando, et al.
Publicado: (2017)

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
por: Modjtahedi, H., et al.
Publicado: (1996)

Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab
por: He, Xuzhi, et al.
Publicado: (2018)

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
por: Lu, Xiaona, et al.
Publicado: (2023)

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
por: Negri, D. R., et al.
Publicado: (1995)

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
por: Graeven, U, et al.
Publicado: (2006)

A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer
por: Lu, Heming, et al.
Publicado: (2018)

Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis
por: Luo, Wenqing, et al.
Publicado: (2021)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c2d3jce4pp33se558c20q6gffa